Califf R M, Topol E J, George B S, Boswick J M, Lee K L, Stump D, Dillon J, Abbottsmith C, Candela R J, Kereiakes D J
Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710.
Circulation. 1988 May;77(5):1090-9. doi: 10.1161/01.cir.77.5.1090.
To examine the outcome of patients with persistent coronary artery occlusion despite treatment with intravenous tissue-type plasminogen activator (t-PA), the clinical course of 96 patients with persistent occlusion after 90 min of therapy was evaluated. All patients underwent cardiac catheterization 90 min after initiation of intravenous t-PA. Immediate coronary angioplasty (PTCA) was attempted when the infarct-related artery failed to reperfuse unless the vessel was technically unsuitable or the infarct was thought to be small. No baseline differences could be found between these 96 patients and 288 patients who achieved perfusion with the same protocol. Although patients with and without successful perfusion after t-PA had similar clinical courses before cardiac catheterization, those without perfusion had more complications (ventricular fibrillation, severe bradycardia, hypotension) during catheterization. PTCA achieved reperfusion with less than 50% residual stenosis in 73% of the 86 patients in whom it was attempted, while 16% were left with a high-grade (greater than 50%) residual stenosis and PTCA failed in 11%. Mortality was highest in the nine patients with complete PTCA failure (44%), compared with a 6% mortality in the 63 patients with an insignificant residual stenosis after PTCA and a 14% mortality in the 14 patients with reperfusion, but a greater than 50% residual stenosis after PTCA. In 10 patients with small infarcts (six), unsuitable anatomy (two), or "spontaneous" drug induced (but later) opening before contemplated PTCA (two), PTCA was not attempted and no mortality occurred. The in-hospital reocclusion rate after successful PTCA was 29%, despite the use of heparin and antiplatelet agents.(ABSTRACT TRUNCATED AT 250 WORDS)
为研究尽管接受静脉注射组织型纤溶酶原激活剂(t-PA)治疗但冠状动脉仍持续闭塞的患者的预后情况,对96例在治疗90分钟后仍存在持续闭塞的患者的临床病程进行了评估。所有患者在静脉注射t-PA开始90分钟后均接受了心脏导管检查。当梗死相关动脉未能再灌注时,除非血管在技术上不适合或梗死被认为较小,否则尝试立即进行冠状动脉血管成形术(PTCA)。在这96例患者与按照相同方案实现灌注的288例患者之间未发现基线差异。尽管t-PA治疗后灌注成功和未成功的患者在心脏导管检查前的临床病程相似,但未灌注的患者在导管检查期间出现更多并发症(室颤、严重心动过缓、低血压)。在尝试PTCA的86例患者中,73%实现了再灌注且残余狭窄小于50%,16%遗留高度(大于50%)残余狭窄,11%的PTCA失败。PTCA完全失败的9例患者死亡率最高(44%),相比之下,PTCA后残余狭窄不明显的63例患者死亡率为6%,PTCA后实现再灌注但残余狭窄大于50%的14例患者死亡率为14%。在10例梗死较小(6例)、解剖结构不适合(2例)或在考虑进行PTCA之前出现“自发”药物诱导(但较晚)开通(2例)的患者中,未尝试PTCA且未发生死亡。尽管使用了肝素和抗血小板药物,但成功PTCA后的院内再闭塞率为29%。(摘要截短于250字)